Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Mendelian randomization of plasma proteomics identifies novel ALS-associated proteins and their GO enrichment and KEGG pathway analyses.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968555 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2377 (Electronic) Linking ISSN: 14712377 NLM ISO Abbreviation: BMC Neurol Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2001-
    • الموضوع:
    • نبذة مختصرة :
      Background: Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurological disorder with an increasing incidence rate. Despite advances in ALS research over the years, the precise etiology and pathogenic mechanisms remain largely elusive.
      Objective: To identify novel plasma proteins associated with ALS through Mendelian randomization methods in large-scale plasma proteomics and to provide potential biomarkers and therapeutic targets for ALS treatment.
      Methods: This study employed a large-scale plasma proteomic Mendelian randomization approach using genetic data from 80,610 individuals of European ancestry (including 20,806 ALS patients and 59,804 controls) derived from a genome-wide association study (GWAS). Protein quantitative trait loci (pQTLs) data were obtained from Ferkingstad et al. (2021), which measured 4,907 proteins in 35,559 Icelandic individuals. Multiple Mendelian randomization (MR) techniques were utilized, including weighted median, MR-Egger, Wald ratio, inverse-variance weighting (IVW), basic model, and weighted model. Heterogeneity was evaluated using Cochran's Q test. Horizontal pleiotropy was assessed through the MR-Egger intercept test and MR-PRESSO outlier detection. Sensitivity analysis was performed via leave-one-out analysis.
      Results: MR analysis revealed potential causal associations between 491 plasma proteins and ALS, identifying 19 novel plasma proteins significantly linked to the disease. Proteins such as C1QC, UMOD, SLITRK5, ASAP2, TREML2, DAPK2, ARHGEF10, POLM, SST, and SIGLEC1 showed positive correlations with ALS risk, whereas ADPGK, BTNL9, COLEC12, ADGRF5, FAIM, CRTAM, PRSS3, BAG5, and PSMD11 exhibited negative correlations. Reverse MR analyses confirmed that ALS negatively correlates with ADPGK and ADGRF5 expression. Enrichment analyses, including Gene Ontology (GO) functional analysis, indicated involvement in critical biological processes such as external encapsulating structure organization, extracellular matrix organization, chemotaxis, and taxis. KEGG pathway analysis highlighted significant enrichment in the PI3K-Akt signaling pathway, cytokine-cytokine receptor interactions, and axon guidance.
      Conclusion: This study enhances the understanding of ALS pathophysiology and proposes potential biomarkers and mechanistic insights for therapeutic development. Future research should explore the clinical translation of these findings to improve ALS patient outcomes and quality of life.
      Competing Interests: Declarations. Ethics approval and consent to participate: According to institutional and local regulations, ethical review and approval were not necessary for the study that used publicly accessible databases.According to institutional policies and national law, patients/participants or their legal guardians/next of kin were not required to give written informed consent in order to take part in this study. Clinical trial number: not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      (© 2025. The Author(s).)
    • References:
      J Neurol. 2024 Apr;271(4):1921-1936. (PMID: 38112783)
      J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):861-869. (PMID: 30992335)
      Front Neurosci. 2023 May 12;17:1170996. (PMID: 37250416)
      Int J Surg. 2024 Feb 01;110(2):766-776. (PMID: 38016292)
      Lancet. 2022 Oct 15;400(10360):1363-1380. (PMID: 36116464)
      Synapse. 2023 Jul;77(4):e22266. (PMID: 36811190)
      Cell. 2008 Mar 7;132(5):846-59. (PMID: 18329370)
      J Transl Med. 2023 Sep 15;21(1):628. (PMID: 37715200)
      Ann Neurol. 2014 Nov;76(5):727-37. (PMID: 25164601)
      Neurol India. 2011 May-Jun;59(3):408-12. (PMID: 21743172)
      Antioxidants (Basel). 2021 Jun 24;10(7):. (PMID: 34202494)
      Immunology. 2013 Mar;138(3):198-207. (PMID: 23181380)
      Prog Neurobiol. 2009 Aug;88(4):286-301. (PMID: 19523502)
      Mol Psychiatry. 2008 Nov;13(11):1060-8. (PMID: 17893707)
      Int J Mol Sci. 2021 Apr 04;22(7):. (PMID: 33916620)
      Nature. 2000 Jun 8;405(6787):697-700. (PMID: 10864328)
      Front Oncol. 2024 Mar 25;14:1358904. (PMID: 38590647)
      Exp Physiol. 2011 Jul;96(7):699-707. (PMID: 21571817)
      Neuroepidemiology. 2021;55(5):342-353. (PMID: 34247168)
      Eur J Epidemiol. 2017 May;32(5):377-389. (PMID: 28527048)
      Mol Neurobiol. 2022 Nov;59(11):6971-6982. (PMID: 36056982)
      Exp Mol Med. 2009 Sep 30;41(9):611-7. (PMID: 19478559)
      Eur J Epidemiol. 2022 Jul;37(7):683-700. (PMID: 35622304)
      Front Mol Biosci. 2020 Feb 27;7:32. (PMID: 32175331)
      RMD Open. 2022 Feb;8(1):. (PMID: 35177553)
      J Immunol. 2015 Oct 1;195(7):3365-73. (PMID: 26290605)
      Cell Rep. 2020 Feb 18;30(7):2374-2386.e5. (PMID: 32075770)
      Trends Neurosci. 2011 Mar;34(3):143-53. (PMID: 21315458)
      Front Neurosci. 2020 Feb 21;14:110. (PMID: 32153351)
      Front Immunol. 2023 Aug 16;14:1246768. (PMID: 37662922)
      Neuroscience. 2009 Apr 21;160(1):97-102. (PMID: 19249338)
      Int J Mol Sci. 2022 Nov 09;23(22):. (PMID: 36430248)
      J Neurochem. 2006 Nov;99(3):759-69. (PMID: 16903872)
      Front Neurosci. 2019 May 15;13:455. (PMID: 31156362)
      J Neuroimmunol. 2006 Feb;171(1-2):145-55. (PMID: 16300832)
      J Parkinsons Dis. 2022;12(1):117-128. (PMID: 34602499)
      Nat Neurosci. 2016 Apr;19(4):557-559. (PMID: 26900927)
      Am J Physiol Cell Physiol. 2022 Aug 1;323(2):C640-C647. (PMID: 35848619)
      Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20960-5. (PMID: 19933335)
      Drugs. 2023 Jul;83(11):1039-1043. (PMID: 37316681)
      J Neurosci. 2007 Oct 17;27(42):11228-41. (PMID: 17942717)
      Brain Behav Immun. 2011 Jul;25(5):1025-35. (PMID: 21176785)
      Sci Rep. 2020 Oct 23;10(1):18603. (PMID: 33097756)
      Sci Rep. 2019 Oct 3;9(1):14248. (PMID: 31582762)
      Respir Res. 2019 Jan 17;20(1):11. (PMID: 30654796)
      Oncogene. 2008 Sep 25;27(43):5706-16. (PMID: 18521079)
      Brain. 2022 Oct 21;145(10):3444-3453. (PMID: 35656776)
      Acta Neuropathol. 2017 Jul;134(1):113-127. (PMID: 28527045)
      Kidney Int. 2015 Oct;88(4):676-83. (PMID: 25738250)
      Oncogene. 1999 Jun 10;18(23):3471-80. (PMID: 10376525)
      J Transl Med. 2022 Oct 20;20(1):475. (PMID: 36266699)
      Diabetes. 2015 Oct;64(10):3452-63. (PMID: 26038578)
      Neurobiol Dis. 2011 Jun;42(3):211-20. (PMID: 21220013)
      Neurology. 1998 Aug;51(2):399-404. (PMID: 9710010)
      BMC Med. 2023 Feb 21;21(1):66. (PMID: 36810112)
      Eur J Neurol. 2020 Oct;27(10):1918-1929. (PMID: 32526057)
      EBioMedicine. 2022 Apr;78:103948. (PMID: 35306338)
      Nat Commun. 2023 Oct 14;14(1):6493. (PMID: 37838725)
      Mol Cell Neurosci. 2003 Sep;24(1):117-29. (PMID: 14550773)
      Nat Immunol. 2018 Dec;19(12):1352-1365. (PMID: 30420626)
      Nat Metab. 2020 Oct;2(10):1135-1148. (PMID: 33067605)
      Stroke. 2021 Aug;52(9):2992-3003. (PMID: 34399585)
      Front Cardiovasc Med. 2024 Jun 13;11:1363200. (PMID: 38938655)
      Acta Biomater. 2023 Dec;172:355-368. (PMID: 37839632)
      Am J Pathol. 1992 Mar;140(3):691-707. (PMID: 1347673)
      Neural Plast. 2016;2016:8301737. (PMID: 26881134)
      Stat Med. 2008 Apr 15;27(8):1133-63. (PMID: 17886233)
      Nature. 2022 Nov;611(7936):585-593. (PMID: 36352225)
      Biomed Res Int. 2022 Jul 14;2022:4678026. (PMID: 35872846)
      PLoS One. 2013 Apr 05;8(4):e60655. (PMID: 23637756)
      Int J Epidemiol. 2017 Dec 1;46(6):1734-1739. (PMID: 28398548)
      J Strength Cond Res. 2022 Sep 1;36(9):2509-2514. (PMID: 33278272)
      J Leukoc Biol. 2014 Feb;95(2):293-303. (PMID: 24163421)
      Biochem Biophys Res Commun. 2015 Feb 13;457(3):419-25. (PMID: 25582777)
      Neuron. 2004 Dec 16;44(6):931-45. (PMID: 15603737)
      Amyotroph Lateral Scler Frontotemporal Degener. 2022 Feb;23(1-2):42-48. (PMID: 34569358)
      Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231218163. (PMID: 38112409)
      Ann Clin Transl Neurol. 2019 Mar 07;6(4):748-754. (PMID: 31019999)
      Res Synth Methods. 2019 Dec;10(4):486-496. (PMID: 30861319)
      Nature. 2012 Sep 13;489(7415):304-8. (PMID: 22972301)
      J Alzheimers Dis. 2020;76(3):799-806. (PMID: 32568208)
      Front Immunol. 2022 Apr 11;13:874978. (PMID: 35479082)
      Mol Neurodegener. 2023 Aug 30;18(1):59. (PMID: 37649100)
      Immunol Lett. 2010 Jul 8;131(2):139-50. (PMID: 20381531)
      Biomolecules. 2023 Oct 08;13(10):. (PMID: 37892176)
      Front Neurol. 2019 Mar 18;10:191. (PMID: 30936848)
      Nat Commun. 2022 Oct 17;13(1):6143. (PMID: 36253349)
      J Clin Invest. 2016 Feb;126(2):745-61. (PMID: 26752644)
      Int J Epidemiol. 2016 Dec 1;45(6):1961-1974. (PMID: 27616674)
      J Neuroinflammation. 2020 Nov 25;17(1):354. (PMID: 33239010)
      J Transl Med. 2023 Sep 21;21(1):646. (PMID: 37735436)
      Front Mol Neurosci. 2022 Oct 26;15:1014497. (PMID: 36385759)
      Structure. 2010 Mar 10;18(3):309-19. (PMID: 20223214)
      Neural Regen Res. 2023 Feb;18(2):434-438. (PMID: 35900442)
      J Clin Lab Anal. 2020 Nov;34(11):e23469. (PMID: 32822099)
      Nature. 2016 Nov 10;539(7628):197-206. (PMID: 27830784)
      Arthritis Res Ther. 2018 Jul 27;20(1):152. (PMID: 30053827)
      Hum Genet. 2023 Jun;142(6):809-818. (PMID: 37085628)
      Front Immunol. 2024 Mar 19;15:1366736. (PMID: 38566994)
      PLoS One. 2008 Jan 16;3(1):e1449. (PMID: 18197259)
      Oxid Med Cell Longev. 2017;2017:5094934. (PMID: 28348719)
      Pharmacol Rev. 2018 Oct;70(4):763-835. (PMID: 30232095)
      Cell Mol Life Sci. 2022 Jan 11;79(1):66. (PMID: 35015148)
      BMC Med Genomics. 2023 Oct 5;16(1):234. (PMID: 37798795)
      Cell. 2023 Sep 28;186(20):4404-4421.e20. (PMID: 37774679)
      Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7176-85. (PMID: 26669444)
      J R Soc Med. 2014 Jan;107(1):14-21. (PMID: 24399773)
      Biostatistics. 2024 Oct 1;25(4):1015-1033. (PMID: 38459704)
      Front Neurosci. 2014 Aug 14;8:252. (PMID: 25177267)
      J Immunol. 2010 Nov 15;185(10):5907-14. (PMID: 20944003)
      J Neuropathol Exp Neurol. 2016 Feb 25;75(4):326-333. (PMID: 26921371)
      Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1051-67. (PMID: 16713195)
      Cell Rep. 2022 Nov 15;41(7):111645. (PMID: 36384129)
      J Neuroinflammation. 2023 Jan 6;20(1):5. (PMID: 36609298)
      Int J Epidemiol. 2021 Jul 9;50(3):829-840. (PMID: 33313759)
      BMC Dev Biol. 2021 Feb 1;21(1):4. (PMID: 33517884)
      Genes (Basel). 2024 Apr 16;15(4):. (PMID: 38674431)
      Nat Commun. 2016 Aug 11;7:12408. (PMID: 27510634)
      Front Immunol. 2017 Aug 21;8:1005. (PMID: 28871262)
      Science. 2021 Nov 12;374(6569):eabj1541. (PMID: 34648354)
      Nat Neurosci. 2024 Apr;27(4):643-655. (PMID: 38424324)
      Mol Autism. 2018 Feb 13;9:11. (PMID: 29456827)
      Nat Genet. 2021 Dec;53(12):1712-1721. (PMID: 34857953)
    • Contributed Indexing:
      Keywords: ALS; Amyotrophic lateral sclerosis; Drug target prediction; GO functional analysis; KEGG pathway analysis; Mendelian randomization; Plasma proteins; Protein quantitative trait loci
    • الرقم المعرف:
      0 (Biomarkers)
      0 (Blood Proteins)
    • الموضوع:
      Date Created: 20250303 Date Completed: 20250304 Latest Revision: 20250306
    • الموضوع:
      20250306
    • الرقم المعرف:
      PMC11874834
    • الرقم المعرف:
      10.1186/s12883-025-04091-x
    • الرقم المعرف:
      40033250